News Agency
Men's Weekly

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

  • Written by PR Newswire

- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and repeat doses of the anti-CTLA-4 therapy -

- Preliminary survival analysis of ADG126 10 mg/kg dosing regimens in patients without liver and peritoneal...

Read more: Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody®...

Delivering Consistent Brand Messaging Across Global Markets: Building Unity Without Losing Local Relevance

Global expansion is both opportunistic and complicated. As companies venture into new, international territories, they must consider language differences, cultural dynamics, regulatory systems, and consumer needs. However, localization does not mean that a consistent brand message should be sacrificed. A... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion